Stability studies initiated with Xspray’s HyNap-Dasa tablets
STOCKHOLM – February 11, 2020. Xspray Pharma (Nasdaq First North Growth Market: XSPRAY) announces that the stability studies with the company’s commercially manufactured HyNap-Dasa tablets began today, February 11. The readout of the study results after six months will be a part of the company’s ANDA application (Abbreviated New Drug Application) for market approval in the US for the HyNap-Dasa product. The application is planned to be submitted to the FDA in the third quarter of 2020. This means that the development of the company's first product candidate HyNap-Dasa, an amorphous version of